Last reviewed · How we verify
Herpes Zoster vaccine GSK1437173A
Herpes Zoster vaccine GSK1437173A is a Recombinant subunit vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults. Also known as: HZ/su vaccine, gE/AS01E, gE/AS01B, HZ/su.
This vaccine stimulates the immune system to recognize and attack varicella-zoster virus (VZV) to prevent herpes zoster (shingles) infection.
This vaccine stimulates the immune system to recognize and attack varicella-zoster virus (VZV) to prevent herpes zoster (shingles) infection. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults.
At a glance
| Generic name | Herpes Zoster vaccine GSK1437173A |
|---|---|
| Also known as | HZ/su vaccine, gE/AS01E, gE/AS01B, HZ/su |
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant subunit vaccine |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GSK1437173A is a recombinant subunit vaccine containing VZV glycoprotein E (gE) combined with an AS01B adjuvant system to enhance immune response. The vaccine primes both cellular and humoral immunity against VZV, reducing the risk of herpes zoster reactivation and post-herpetic neuralgia in older adults and immunocompromised populations.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster in immunocompromised adults
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (PHASE1, PHASE2)
- A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (PHASE3)
- A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (PHASE3)
- Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years (PHASE4)
- Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine (PHASE2)
- Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herpes Zoster vaccine GSK1437173A CI brief — competitive landscape report
- Herpes Zoster vaccine GSK1437173A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Herpes Zoster vaccine GSK1437173A
What is Herpes Zoster vaccine GSK1437173A?
How does Herpes Zoster vaccine GSK1437173A work?
What is Herpes Zoster vaccine GSK1437173A used for?
Who makes Herpes Zoster vaccine GSK1437173A?
Is Herpes Zoster vaccine GSK1437173A also known as anything else?
What drug class is Herpes Zoster vaccine GSK1437173A in?
What development phase is Herpes Zoster vaccine GSK1437173A in?
What are the side effects of Herpes Zoster vaccine GSK1437173A?
What does Herpes Zoster vaccine GSK1437173A target?
Related
- Drug class: All Recombinant subunit vaccine drugs
- Target: All drugs targeting Varicella-zoster virus glycoprotein E (gE)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Indication: Drugs for Prevention of herpes zoster in immunocompromised adults
- Also known as: HZ/su vaccine, gE/AS01E, gE/AS01B, HZ/su
- Compare: Herpes Zoster vaccine GSK1437173A vs similar drugs
- Pricing: Herpes Zoster vaccine GSK1437173A cost, discount & access